Systemic antibiotic therapy for chronic osteomyelitis in adults

Clinical Infectious Diseases

Volumn 54, Issue 3, 2012, Pages 393-407

  Spellberg, Brad ^a,b   Lipsky, Benjamin A ^c,d  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ENOXACIN; FOSFOMYCIN; FUSIDIC ACID; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; OXACILLIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULBACTAM; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ADULT DISEASE; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OSTEOMYELITIS; DEBRIDEMENT; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG PENETRATION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; HUMANS; INJECTIONS, INTRAVENOUS; OSTEOMYELITIS;

EID: 84855867220     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir842     Document Type: Article

References (172)

1. Moodie RL. Osteomyelitis in the Permian. Science 1921;53:333.
2. Norden CW. Lessons learned from animal models of osteomyelitis. Rev Infect Dis 1988;10:103-10.
3. Waldvogel FA, Papageorgiou PS. Osteomyelitis: the past decade. N Engl J Med 1980;303:360-70. (Pubitemid 10035062)
4. Haidar R, der Boghossian A, Atiyeh B. Duration of post-surgical antibiotics in chronic osteomyelitis: empiric or evidence-based? Int J Infect Dis 2010;14:e752-8.
5. Al-Maiyah M, Hemmady MV, Shoaib A, Morgan-Jones RL. Recurrence of chronic osteomyelitis in a regenerated fibula after 65 years. Orthopedics 2007;30:403-4. (Pubitemid 46860780)
6. Donati L, Quadri P, Reiner M. Reactivation of osteomyelitis caused by Staphylococcus aureus after 50 years. J Am Geriatr Soc 1999;47:1035-7. (Pubitemid 29380503)
7. West WF, Kelly PJ, Martin WJ. Chronic osteomyelitis. I. Factors affecting the results of treatment in 186 patients. JAMA 1970;213:1837-42.
8. Gallie WE. First recurrence of osteomyelitis eighty years after infection. J Bone Joint Surg Br 1951;33-B: 110-1.
9. Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis: why do antibiotics fail so often? Postgrad Med J 2000;76:479-83. (Pubitemid 30636113)
10. Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med 1970;282:198-206.
11. Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects (second of three parts). N Engl J Med 1970;282:260-6.
12. Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. 3. Osteomyelitis associated with vascular insufficiency. N Engl J Med 1970;282:316-22.
13. Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis 2001;1:175-88. (Pubitemid 33586051)
14. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis 2005;9:127-38. (Pubitemid 40523757)
15. Rod-Fleury T, Dunkel N, Assal M, et al. Duration of post-surgical antibiotic therapy for adult chronic osteomyelitis: a single-centre experience. Int Orthop 2011;35:1725-31.
16. Wewalka G, Endler M, Kraft A. Antibiotic concentrations in wound secretions and bone during the simultaneous administration of mezlocillin and oxacillin. Infection 1982;10(Suppl 3): S213-6.
17. Warnke JP, Wildfeuer A, Eibel G, Pfaff G, Klammer A. Pharmacokinetics of ampicillin/sulbactam in patients undergoing spinal microneurosurgical procedures. Int J Clin Pharmacol Ther 1998;36:253-7. (Pubitemid 28230170)
18. Wildfeuer A, Mallwitz J, Gotthardt H, et al. Pharmacokinetics of ampicillin, sulbactam and cefotiam in patients undergoing orthopedic surgery. Infection 1997;25:258-62.
19. Cunha BA, Gossling HR, Pasternak HS, Nightingale CH, Quintiliani R. Penetration of cephalosporins into bone. Infection 1984;12:80-4. (Pubitemid 14135755)
20. Polk R, Hume A, Kline BJ, Cardea J. Penetration of moxalactam and cefazolin into bone following simultaneous bolus or infusion. Clin Orthop 1983;177:216-21. (Pubitemid 13077766)
21. Williams DN, Gustilo RB, Beverly R, Kind AC. Bone and serum concentrations of five cephalosporin drugs. Relevance to prophylaxis and treatment in orthopedic surgery. Clin Orthop 1983;179:253-65. (Pubitemid 13017335)
22. Schurman DJ, Hirshman HP, Kajiyama G, Moser K, Burton DS. Cefazolin concentrations in bone and synovial fluid. J Bone Joint Surg Am 1978;60:359-62. (Pubitemid 8333077)
23. Fass RJ. Treatment of osteomyelitis and septic arthritis with cefazolin. Antimicrob Agents Chemother 1978;13:405-11. (Pubitemid 8300975)
24. Graziani AL, Lawson LA, Gibson GA, Steinberg MA, MacGregor RR. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988;32:1320-2.
25. Traunmuller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 2010;65:1252-7.
26. Lovering AM, Walsh TR, Bannister GC, MacGowan AP. The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone. J Antimicrob Chemother 2001;47:483-6. (Pubitemid 32303420)
27. Soudry B, Sirot J, Lopitaux R, Dumont C, Delisle JJ, Parenton M. Diffusion of ceftriaxone in human bone tissue. Pathol Biol (Paris) 1986;34:859-62. (Pubitemid 17192589)
28. Scaglione F, De Martini G, Peretto L, et al. Pharmacokinetic study of cefodizime and ceftriaxone in sera and bones of patients undergoing hip arthroplasty. Antimicrob Agents Chemother 1997;41:2292-4. (Pubitemid 27422231)
29. Raymakers JT, Schaper NC, van der Heyden JJ, Tordoir JH, Kitslaar PJ. Penetration of ceftazidime into bone from severely ischaemic limbs. J Antimicrob Chemother 1998;42:543-5. (Pubitemid 28473019)
30. Leigh DA, Griggs J, Tighe CM, et al. Pharmacokinetic study of ceftazidime in bone and serum of patients undergoing hip and knee arthroplasty. J Antimicrob Chemother 1985;16:637-42. (Pubitemid 16215656)
31. Handa N, Kawakami T, Kitaoka K, et al. The clinical efficacy of imipenem/cilastatin sodium in orthopedic infections and drug levels in the bone tissue. Jpn J Antibiot 1997;50:622-7. (Pubitemid 27340358)
32. Breilh D, Boselli E, Bel JC, Chassard D, Saux MC, Allaouchiche B. Diffusion of cefepime into cancellous and cortical bone tissue. J Chemother 2003;15:134-8. (Pubitemid 36609748)
33. Wittmann DH, Kuipers TH, Fock R, Holl M, Bauernfeind A. Bone concentrations of imipenem after a dose of imipenem/cilastatin. Infection 1986;14(Suppl 2): S130-7. (Pubitemid 16068089)
34. MacGregor RR, Gibson GA, Bland JA. Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections. Antimicrob Agents Chemother 1986;29:188-92. (Pubitemid 16162923)
35. Sano T, Sakurai M, Dohi S, et al. Investigation of meropenem levels in the human bone marrow blood, bone, joint fluid and joint tissues. Jpn J Antibiot 1993;46:159-63. (Pubitemid 23121428)
36. Incavo SJ, Ronchetti PJ, Choi JH, Wu H, Kinzig M, Sorgel F. Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues. Antimicrob Agents Chemother 1994;38:905-7. (Pubitemid 24114044)
37. Bergogne-Berezin E. Tissue concentrations of piperacillin in humans. Presse Med 1986;15:2324-7.
38. Kato M, Morimoto R. Concentration of piperacillin in bone. Jpn J Antibiot 1984;37:279-84. (Pubitemid 15140883)
39. Foulds G, Knirsch AK, Stankewich JP, Weidler DR. The parenteral kinetics of ampicillin/sulbactam in man. Int J Clin Pharmacol Res 1985;5:79-86. (Pubitemid 15054772)
40. Wildfeuer A, Schwiersch U, Engel K, et al. Pharmacokinetics of sulbactam and ampicillin intravenously applied in combination to healthy volunteers and patients: determination of the ratio of the two drugs in serum and in various tissues. Arzneimittelforschung 1988;38:1640-3. (Pubitemid 18268580)
41. Quintiliani R, Nightingale CH. Cefazolin. Ann Intern Med 1978;89:650-6. (Pubitemid 9016591)
42. Garcia I, Fainstein V, Smith RG, Bodey GP. Multiple-dose pharmacokinetics of ceftazidime in cancer patients. Antimicrob Agents Chemother 1983;24:141-4. (Pubitemid 13029313)
43. Standiford HC, Drusano GL, Bustamante CI, et al. Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. Antimicrob Agents Chemother 1986;29:412-7. (Pubitemid 16143246)
44. Paradis D, Vallee F, Allard S, et al. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother 1992;36:2085-92.
45. Signs SA, Tan JS, Salstrom SJ, File TM. Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. Antimicrob Agents Chemother 1992;36:1400-3.
46. Raymakers JT, Houben AJ, van der Heyden JJ, Tordoir JH, Kitslaar PJ, Schaper NC. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. Diabet Med 2001;18:229-34. (Pubitemid 32397862)
47. Massias L, Dubois C, de Lentdecker P, Brodaty O, Fischler M, Farinotti R. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother 1992;36:2539-41.
48. Martin C, Alaya M, Mallet MN, et al. Penetration of vancomycin into mediastinal and cardiac tissues in humans. Antimicrob Agents Chemother 1994;38:396-9. (Pubitemid 24054274)
49. Holtom PD, Zalavras CG, Lamp KC, Park N, Friedrich LV. Clinical experience with daptomycin treatment of foot or ankle osteomyelitis: a preliminary study. Clin Orthop Relat Res 2007;461:35-9. (Pubitemid 47344091)
50. Fong IW, Ledbetter WH, Vandenbroucke AC, Simbul M, Rahm V. Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob Agents Chemother 1986;29:405-8. (Pubitemid 16143244)
51. Meissner A, Borner K. Concentration of ciprofloxacin in bone tissue. Aktuelle Traumatol 1993;23:80-4. (Pubitemid 23170985)
52. Wacha H, Wagner D, Schafer V, Knothe H. Concentration of ciprofloxacin in bone tissue after single parenteral administration to patients older than 70 years. Infection 1990;18:173-6. (Pubitemid 20186033)
53. von Baum H, Bottcher S, Abel R, Gerner HJ, Sonntag HG. Tissue and serum concentrations of levofloxacin in orthopaedic patients. Int J Antimicrob Agents 2001;18:335-40. (Pubitemid 33016346)
54. Rimmele T, Boselli E, Breilh D, et al. Diffusion of levofloxacin into bone and synovial tissues. J Antimicrob Chemother 2004;53:533-5. (Pubitemid 38380257)
55. Fong IW, Rittenhouse BR, Simbul M, Vandenbroucke AC. Bone penetration of enoxacin in patients with and without osteomyelitis. Antimicrob Agents Chemother 1988;32:834-7.
56. Malincarne L, Ghebregzabher M, Moretti MV, et al. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. J Antimicrob Chemother 2006;57:950-4.
57. Kutscha-Lissberg F, Hebler U, Muhr G, Koller M. Linezolid penetration into bone and joint tissues infected with methicillinresistant staphylococci. Antimicrob Agents Chemother 2003;47:3964-6. (Pubitemid 37485016)
58. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002;50:73-7. (Pubitemid 34785257)
59. Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 2002;50:747-50. (Pubitemid 35331696)
60. Saux MC, Le Rebeller A, Leng B, Mintrosse J. Bone diffusion of trimethoprim and sulfamethoxazole high pressure liquid chromatography (HPLC) (author's transl). Pathol Biol (Paris) 1982;30:385-8. (Pubitemid 12081194)
61. Bystedt H, D'Ahlbäck A, Dornbusch K, Nord CE. Concentrations of azidocillin, erythromycin, doxycycline and clindamycin in human mandibular bone. Int J Oral Surg 1978;7:442-9. (Pubitemid 9046401)
62. Dornbusch K. The detection of doxycycline activity in human bone. Scand J Infect Dis Suppl 1976;9:47-53. (Pubitemid 8003900)
63. Gnarpe H, Dornbusch K, Hagg O. Doxycycline concentration levels in bone, soft tissue and serum after intravenous infusion of doxycycline: a clinical study. Scand J Infect Dis Suppl 1976;9:54-7. (Pubitemid 8003901)
64. Baird P, Hughes S, Sullivan M, Willmot I. Penetration into bone and tissues of clindamycin phosphate. Postgrad Med J 1978;54:65-7. (Pubitemid 8276956)
65. Nicholas P, Meyers BR, Levy RN, Hirschman SZ. Concentration of clindamycin in human bone. Antimicrob Agents Chemother 1975;8:220-1.
66. Schurman DJ, Johnson BL Jr, Finerman G, Amstutz HC. Antibiotic bone penetration: concentrations of methicillin and clindamycin phosphate in human bone taken during total hip replacement. Clin Orthop 1975:142-6.
67. Hahn F, Borner K, Koeppe P. Concentration of metronidazole in bones. Aktuelle Traumatol 1988;18:84-6.
68. Bergan T, Solhaug JH, Soreide O, Leinebo O. Comparative pharmacokinetics of metronidazole and tinidazole and their tissue penetration. Scand J Gastroenterol 1985;20:945-50. (Pubitemid 16236018)
69. Roth B. Penetration of parenterally administered rifampicin into bone tissue. Chemotherapy 1984;30:358-65. (Pubitemid 15209218)
70. Hierholzer G, Rehn J, Knothe H, Masterson J. Antibiotic therapy of chronic post-traumatic osteomyelitis. J Bone Joint Surg Br 1974;56-B: 721-9.
71. Pahle JA. Experiences with fucidin in the treatment of osteomyelitis. Acta Orthop Scand 1969;40:675.
72. Meissner A, Haag R, Rahmanzadeh R. Adjuvant fosfomycin medication in chronic osteomyelitis. Infection 1989;17:146-51. (Pubitemid 19151438)
73. Schintler MV, Traunmuller F, Metzler J, et al. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother 2009;64:574-8.
74. Dudley MN, Ericson J, Zinner SH. Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. Antimicrob Agents Chemother 1987;31:1782-6. (Pubitemid 17157644)
75. Burkhardt O, Borner K, von der Hoh N, et al. Single-and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J Antimicrob Chemother 2002;50:707-12. (Pubitemid 35331688)
76. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001;45:1843-6. (Pubitemid 32466358)
77. Cunha BA, Sibley CM, Ristuccia AM. Doxycycline Ther Drug Monit 1982;4:115-35.
78. Javaloyas de Morlius M, Monreal Portella M. Oral antibiotic therapy in the adult bacterial osteomyelitis: results after two years of follow-up. Med Clin (Barc) 1999;113:488-9.
79. Stein GE, Gurwith D, Gurwith M. Randomized clinical trial of rifampintrimethoprim and sulfamethoxazole-trimethoprim in the treatment of localized urinary tract infections. Antimicrob Agents Chemother 1988;32:802-6.
80. Gjerloff C, Arnold E. Pharmacokinetics of intravenous metronidazole in man. Acta Pharmacol Toxicol (Copenh) 1982;51:132-5. (Pubitemid 12044542)
81. Nilsson-Ehle I, Ursing B, Nilsson-Ehle P. Liquid chromatographic assay for metronidazole and tinidazole: pharmacokinetic and metabolic studies in human subjects. Antimicrob Agents Chemother 1981;19:754-60. (Pubitemid 11092068)
82. Dworkin R, Modin G, Kunz S, Rich R, Zak O, Sande M. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Antimicrob Agents Chemother 1990;34:1014-16. (Pubitemid 20177345)
83. Iversen P, Nielsen OS, Jensen KM, Madsen PO. Comparison of concentrations of rifampin and a new rifamycin derivative, DL 473, in canine bone. Antimicrob Agents Chemother 1983;23:338-40. (Pubitemid 13137552)
84. de Barros JW, Calapodopulos CJ, Oliveira DJ, Miki Junior P. The treatment of chronic osteomyelitis. Rev Soc Bras Med Trop 1992;25:235-9.
85. Norden CW, Shaffer M. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with vancomycin and rifampin. J Infect Dis 1983;147:352-7. (Pubitemid 13195121)
86. Yu VL, Zuravleff JJ, Peacock JE, De Hertogh D, Tashjian L. Addition of rifampin to carboxypenicillin-aminoglycoside combination for the treatment of Pseudomonas aeruginosa infection: clinical experience with four patients. Antimicrob Agents Chemother 1984;26:575-7. (Pubitemid 14018099)
87. Zuravleff JJ, Chervenick P, Yu VL, Muder RR, Diven WF. Addition of rifampin to ticarcillin-tobramycin combination for the treatment of Pseudomonas aeruginosa infections: assessment in a neutropenic mouse model. J Lab Clin Med 1984;103:878-85. (Pubitemid 14122452)
88. Chang HR, Vladoianu IR, Pechere JC. Effects of ampicillin, ceftriaxone, chloramphenicol, pefloxacin and trimethoprim-sulphamethoxazole on Salmonella typhi within human monocyte-derived macrophages. J Antimicrob Chemother 1990;26:689-94.
89. Close SJ, McBurney CR, Garvin CG, Chen DC, Martin SJ. Trimethoprim-sulfamethoxazole activity and pharmacodynamics against glycopeptide-intermediate Staphylococcus aureus. Pharmacotherapy 2002;22:983-9. (Pubitemid 34831293)
90. Yeldandi V, Strodtman R, Lentino JR. In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother 1988;22:873-80. (Pubitemid 19023229)
91. Burman LG. The antimicrobial activities of trimethoprim and sulfonamides. Scand J Infect Dis 1986;18:3-13. (Pubitemid 16135616)
92. Centers for Disease Control and Prevention (CDC). Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections-Los Angeles County, California, 2002-2003. MMWR Morb Mortal Wkly Rep 2003;52:88.
93. Eady EA, Cove JH. Staphylococcal resistance revisited: communityacquired methicillin resistant Staphylococcus aureus-an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003;16:103-24. (Pubitemid 36521023)
94. Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002;21:530-4. (Pubitemid 34625834)
95. Bancroft E, Kilgore G, Jones A, et al. Four outbreaks of communityassociated methicillin-resistant Staphylococcus aureus in Los Angeles County. In: The 41st Annual Meeting of the Infectious Disease Society of America. San Diego, CA, 2003.
96. Forti G, Benincori C. Doxycycline and the teeth. Lancet 1969;1:782.
97. Chazan B, Strahilevitz J, Millgram MA, Kaufmann S, Raz R. Bacteroides fragilis vertebral osteomyelitis secondary to anal dilatation. Spine (Phila Pa 1976) 2001;26:E377-8.
98. Riley TV, Karthigasu KT. Chronic osteomyelitis due to Clostridium difficile. Br Med J (Clin Res Ed) 1982;284:1217-8. (Pubitemid 12146386)
99. Melo JC, Raff MJ, Wunderlich HF, Chun CH, Summersgill JT, Varghese R. Metronidazole treatment of Bacteroides fragilis infections. Am J Med Sci 1980;280:143-9. (Pubitemid 11210881)
100. Zimmerman J, Silver J, Shapiro M, Friedman G, Melmed RN. Clindamycin unresponsive anaerobic osteomyelitis treated with oral metronidazole. Scand J Infect Dis 1980;12:79-80. (Pubitemid 10201689)
101. Norden CW, Fierer J, Bryant RE. Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin. Rev Infect Dis 1983;5(Suppl 3): S495-501.
102. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997;41:2670-9. (Pubitemid 27524738)
103. Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis 1983;5(Suppl 3): S428-32.
104. Reeves DS. The pharmacokinetics of fusidic acid. J Antimicrob Chemother 1987;20:467-76. (Pubitemid 17154585)
105. O'Reilly T, Kunz S, Sande E, Zak O, Sande MA, Tauber MG. Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin. Antimicrob Agents Chemother 1992;36:2693-7.
106. Mader JT, Reinarz JA, LeFrock JL. Cefotaxime treatment in patients with osteomyelitis and septic arthritis: a multicenter study. Clin Ther 1982;5(Suppl A): 10-8. (Pubitemid 13225175)
107. LeFrock JL, Carr BB. Clinical experience with cefotaxime in the treatment of serious bone and joint infections. Rev Infect Dis 1982;4(Suppl): S465-71.
108. MacGregor RR, Gentry LO. Imipenem/cilastatin in the treatment of osteomyelitis. Am J Med 1985;78:100-3. (Pubitemid 15073712)
109. Bach MC, Cocchetto DM. Ceftazidime as single-agent therapy for gram-negative aerobic bacillary osteomyelitis. Antimicrob Agents Chemother 1987;31:1605-8. (Pubitemid 17140821)
110. Gomis M, Herranz A, Aparicio P, Filloy JL, Pastor J. Cefotaxime in the treatment of chronic osteomyelitis caused by gram-negative bacilli. J Antimicrob Chemother 1990;26(Suppl A): 45-52. (Pubitemid 20281723)
111. Simons WJ, Lee TJ. Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli. Rev Infect Dis 1985;7(Suppl 4): S783-8.
112. Conrad DA, Williams RR, Couchman TL, Lentnek AL. Efficacy of aztreonam in the treatment of skeletal infections due to Pseudomonas aeruginosa. Rev Infect Dis 1991;13(Suppl 7): S634-9.
113. Lucht RF, Fresard A, Berthelot P, et al. Prolonged treatment of chronic Pseudomonas aeruginosa osteomyelitis with a combination of two effective antibiotics. Infection 1994;22:276-80. (Pubitemid 24255180)
114. Akova M, Ozcebe O, Gullu I, et al. Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections. J Chemother 1996;8:284-9. (Pubitemid 26271104)
115. Munckhof WJ, Carney J, Neilson G, et al. Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2005;25:514-22. (Pubitemid 40732606)
116. Legout L, Senneville E, Stern R, et al. Treatment of bone and joint infections caused by gram-negative bacilli with a cefepimefluoroquinolone combination. Clin Microbiol Infect 2006;12:1030-3. (Pubitemid 44322578)
117. Dombrowski JC, Winston LG. Clinical failures of appropriatelytreated methicillin-resistant Staphylococcus aureus infections. J Infect 2008;57:110-5.
118. Livorsi DJ, Daver NG, Atmar RL, Shelburne SA, White AC Jr, Musher DM. Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect 2008;57:128-31.
119. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drugresistant gram-positive bone and joint infections. Curr Med Res Opin 2005;21:1923-6. (Pubitemid 41803101)
120. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 2007;120(10 Suppl 1):S13-20. (Pubitemid 47464123)
121. Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003;114:723-8. (Pubitemid 36776353)
122. Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003;51:1261-8. (Pubitemid 36622083)
123. Schafer JJ, Mangino JE. Multidrug-resistant Acinetobacter baumannii osteomyelitis from Iraq. Emerg Infect Dis 2008;14:512-4. (Pubitemid 351451411)
124. Chen PL, Yan JJ, Wu CJ, et al. Salvage therapy with tigecycline for recurrent infection caused by ertapenem-resistant extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2010;68:312-4.
125. Kuo SC, Wang FD, Fung CP, et al. Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. J Microbiol Immunol Infect 2011;44:45-51.
126. Darley ES, MacGowan AP. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother 2004;53:928-35. (Pubitemid 38811422)
127. Nix DE, Cumbo TJ, Kuritzky P, DeVito JM, Schentag JJ. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections: efficacy, safety, and pharmacokinetics. Am J Med 1987;82:146-53.
128. Lesse AJ, Freer C, Salata RA, Francis JB, Scheld WM. Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis. Am J Med 1987;82:247-53.
129. Gilbert DN, Tice AD, Marsh PK, Craven PC, Preheim LC. Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli. Am J Med 1987;82:254-8.
130. Hessen MT, Ingerman MJ, Kaufman DH, et al. Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis. Am J Med 1987;82:262-5.
131. Greenberg RN, Kennedy DJ, Reilly PM, et al. Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob Agents Chemother 1987;31:151-5. (Pubitemid 17011228)
132. Mader JT, Cantrell JS, Calhoun J. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. J Bone Joint Surg Am 1990;72:104-10. (Pubitemid 20076564)
133. Giamarellou H, Galanakis N. Use of intravenous ciprofloxacin in difficult-to-treat infections. Am J Med 1987;82:346-51.
134. Scully BE, Neu HC. Treatment of serious infections with intravenous ciprofloxacin. Am J Med 1987;82:369-75.
135. Therapy of acute and chronic gram-negative osteomyelitis with ciprofloxacin: report from a Swedish Study Group. J Antimicrob Chemother 1988;22:221-8.
136. Greenberg RN, Newman MT, Shariaty S, Pectol RW. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob Agents Chemother 2000;44:164-6. (Pubitemid 30010688)
137. Dellamonica P, Bernard E, Etesse H, Garraffo R, Drugeon HB. Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1989;8:1024-30. (Pubitemid 20018472)
138. Ketterl R, Beckurts T, Stubinger B, Claudi B. Use of ofloxacin in open fractures and in the treatment of post-traumatic osteomyelitis. J Antimicrob Chemother 1988;22(Suppl C): 159-66.
139. Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding DN. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am J Med 1989;86:801-8. (Pubitemid 19148097)
140. Drancourt M, Stein A, Argenson JN, Zannier A, Curvale G, Raoult D. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 1993;37:1214-8. (Pubitemid 23166716)
141. Barberan J, Aguilar L, Gimenez MJ, Carroquino G, Granizo JJ, Prieto J. Levofloxacin plus rifampicin conservative treatment of 25 early staphylococcal infections of osteosynthetic devices for rigid internal fixation. Int J Antimicrob Agents 2008;32:154-7.
142. Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997;39:235-40. (Pubitemid 27116419)
143. Senneville E, Joulie D, Legout L, et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 2011;53:334-40.
144. El Helou OC, Berbari EF, Lahr BD, et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis 2010;29:961-7.
145. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, grampositive infections: experience from a compassionate-use program. Clin Infect Dis 2003;36:159-68. (Pubitemid 36143412)
146. Pontifex AH, McNaught DR. The treatment of chronic osteomyelitis with clindamycin. Can Med Assoc J 1973;109:105-7.
147. Craven JL, Pugsley DJ, Blowers R. Trimethoprim-sulphamethoxazole in acute osteomyelitis due to penicillin-resistant staphylococci in Uganda. Br Med J 1970;3:201-3.
148. Saengnipanthkul S, Pongvivat T, Mahaisavariya B, Laupattarakasem W. Co-trimoxazole in the treatment of chronic osteomyelitis. J Med Assoc Thai 1988;71:186-91.
149. Sanchez C, Matamala A, Salavert M, et al. Cotrimoxazole plus rifampicin in the treatment of staphylococcal osteoarticular infection. Enferm Infecc Microbiol Clin 1997;15:10-3. (Pubitemid 27094964)
150. Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998;42:3086-91. (Pubitemid 28553722)
151. Nguyen S, Pasquet A, Legout L, et al. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 2009;15:1163-9.
152. Fernandez-Valencia JE, Saban T, Canedo T, Olay T. Fosfomycin in osteomyelitis. Chemotherapy 1976;22:121-34.
153. Papasian CJ, McGregor DH, Hodges GR, Kennedy J. Peptostreptococcal vertebral osteomyelitis. J Clin Microbiol 1986;24:633-5. (Pubitemid 16014565)
154. Seto BG, Lynch SR, Moy PK. Chronic osteomyelitis of mandible caused by penicillin-resistant Bacteroides ruminicola. Report of a case. Oral Surg Oral Med Oral Pathol 1986;61:29-31. (Pubitemid 16156629)
155. Edmondson HT. Parenteral and oral clindamycin therapy in surgical infections: a preliminary report. Ann Surg 1973;178:637-42.
156. Atkins B, Gottlieb T. Fusidic acid in bone and joint infections. Int J Antimicrob Agents 1999;12(Suppl 2): S79-93. (Pubitemid 29406145)
157. Wolfe CR. Case report: treatment of chronic osteomyelitis. Clin Infect Dis 2011;52(Suppl 7): S538-41.
158. Conterno LO, da Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev 2009; (3): CD004439.
159. Van der Auwera P, Klastersky J, Thys JP, Meunier-Carpentier F, Legrand JC. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 1985;28:467-72. (Pubitemid 16236531)
160. Norden CW, Bryant R, Palmer D, Montgomerie JZ, Wheat J. Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986;79:947-51.
161. Sheftel TG, Mader JT. Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli. Antimicrob Agents Chemother 1986;29:112-5. (Pubitemid 16155232)
162. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004;38:17-24. (Pubitemid 38045868)
163. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998;279:1537-41. (Pubitemid 28233008)
164. Greenberg RN, Tice AD, Marsh PK, et al. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. Am J Med 1987;82:266-9.
165. Peacock JE Jr, Pegram PS, Weber SF, Leone PA. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. Am J Med 1989;87:185S-90S. (Pubitemid 20005178)
166. Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother 1990;34:40-3. (Pubitemid 20019961)
167. Gentry LO, Rodriguez-Gomez G. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob Agents Chemother 1991;35:538-41.
168. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis 1997;24:643-8. (Pubitemid 27143558)
169. Gomis M, Barberan J, Sanchez B, Khorrami S, Borja J, Garcia-Barbal J. Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis. Rev Esp Quimioter 1999;12:244-9. (Pubitemid 29513708)
170. Euba G, Murillo O, Fernandez-Sabe N, et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother 2009;53:2672-6.
171. Schmitz FJ, Fluit AC, Hafner D, et al. Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2000;44:3229-31.
172. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis 2004;38:864-70. (Pubitemid 38387236)